- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06861335
Examination of the Effects of Pelvic Floor Muscle Exercises on Blood Flow in Pregnant Women (Bloodflow)
Examination of the Effects of Pelvic Floor Muscle Exercises on Vulvovaginal, Umbilical, Uterine and Middle Cerebral Artery Blood Flow in Pregnant Women
Study Overview
Status
Intervention / Treatment
Detailed Description
This research will be conducted on pregnant women aged 18 and over, with their first pregnancy, who apply to the Department of Obstetrics and Gynecology at Dokuz Eylul University Faculty of Medicine Hospital. Participants will be informed about the purpose of the study and the assessment methods to be applied, and informed consent forms will be obtained from each participant. The demographic information of the participants will be recorded in the evaluation form.
The sociodemographic characteristics of the individuals will be evaluated through face-to-face interviews, and physical characteristics such as age (years), height (cm), weight (kg), BMI (kg/m²), and demographic data such as education level, occupation, and marital status will be recorded in the data recording form. In addition, past and family medical history, lifestyle habits, medical and surgical history, obstetric history, gynecological history, and pregnancy history will be questioned (Appendix 4). In the study, digital palpation with the PERFECT evaluation system will be used to assess pelvic floor muscle strength, and clitoral Doppler ultrasound will be used to assess vulvovaginal blood flow. Umbilical, uterine artery, and MCA blood flow will be measured by Doppler ultrasound during routine pregnancy check-ups. Assessments will be repeated three times from the 2nd trimester onwards, during the participants' regular doctor check-ups. After the first interview, participants will be randomized into exercise and control groups.
An individualized pelvic floor muscle exercise program will be created for each participant in the exercise group based on their digital palpation and PERFECT values, and will be taught in the first session with the physiotherapist, and they will be asked to do this as a home program. During the weeks they come for pregnancy check-ups, the pelvic floor muscles will be re-evaluated and the exercise program will be updated according to the new evaluation results. An exercise tracking chart will be created and given to control the home program, and participants will be asked to keep this daily and follow-up will be done. Pregnant women in the control group will not be given any exercise program and will continue their routine pregnancy follow-ups. All assessments will be repeated three times during their routine pregnancy check-ups. Separate WhatsApp groups will be created for the control and exercise groups. Reminders will be made in the exercise WhatsApp group to encourage regular exercise. Routine pregnancy information will be shared in the control WhatsApp group
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Manisa, Turkey, 45000
- Manisa Celal Bayar Univercity
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Being 18 years of age or older
- Having at least a primary school education
- Being pregnant for the first time
- Being in the 12th week of pregnancy or later
- Having a singleton pregnancy
- Having signed the informed voluntary consent form
Exclusion Criteria:
- Multiple pregnancies
- Pregnant women with pregnancy-related symptoms (hypertension, preeclampsia, gestational diabetes...)
- Pregnant women considered high-risk by an obstetrician
- Pregnant women at risk of premature birth, early delivery, or miscarriage
- Pregnant women diagnosed with neurological diseases
- Pregnant women with severe back pain (regularly unable to perform tasks)
- Pregnant women diagnosed with psychiatric diseases
- Pregnant women with severe cognitive impairment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Exercise group
Participants will undergo pelvic floor muscle training
|
For each participant included in the exercise group, an individualized pelvic floor muscle exercise program will be created based on the results of digital palpation and the PERFECT assessment system.
The first exercise session will be conducted with the physiotherapist, and the participant will be provided with a home-based program.
During pregnancy check-ups, the pelvic floor muscles will be re-evaluated, and the exercise program will be updated according to the new evaluation results.
To monitor the home-based program, participants will be given an exercise tracking chart that they will be asked to fill out daily
|
|
Other: Control group
Participants received standard prenatal care, education on pelvic floor health, general health education, and lifestyle counseling
|
Participants in the control group of our study will receive standard pregnancy care and check-ups.
Within this scope, the general health status of the pregnant women will be evaluated during routine antenatal follow-up visits, check-ups appropriate to their gestational weeks will be performed, and necessary medical interventions will be carried out.
Additionally, participants will receive detailed education about pelvic floor anatomy, the functions of the pelvic floor muscles, and the changes that occur in these muscles during pregnancy.
Within the scope of general health education, information will be provided about nutrition, hygiene, exercise, and other lifestyle recommendations during pregnancy.
The participants in the control group will not be given the specific pelvic floor muscle training program applied in the experimental arm of the study; they will only receive standard pregnancy care and general information
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
uterine artery blood flow
Time Frame: The first measurement will be performed between the 20th and 24th weeks of pregnancy, the second measurement between the 25th and 28th weeks of pregnancy, and the third measurement between the 35th and 38th weeks of pregnancy.
|
Uterine artery Doppler measurement is an important non-invasive method used to evaluate uteroplacental blood flow during pregnancy. This measurement is performed bilaterally from the region where the uterine arteries cross the external iliac arteries, using an abdominal ultrasonography probe. The 2nd or 3rd trimesters are generally preferred for measurement. Procedure: Patient Position: The pregnant woman is placed comfortably in a supine position. The abdominal area is exposed to allow easy movement of the probe. Equipment: A Doppler ultrasonography device (e.g., Voluson E8, GE Healthcare) and an abdominal probe with an appropriate frequency are used. Probe Placement: First, the probe is placed in the sagittal plane at the level of the internal cervical os. From this point, the probe is moved slightly towards the region where the uterine arteries cross the external iliac arteries. Color Doppler: Color Doppler mode is used to visually identify the uterine arteries. Color Doppler dis |
The first measurement will be performed between the 20th and 24th weeks of pregnancy, the second measurement between the 25th and 28th weeks of pregnancy, and the third measurement between the 35th and 38th weeks of pregnancy.
|
|
umbilical artery blood flow
Time Frame: The first measurement will be performed between the 20th and 24th weeks of pregnancy, the second measurement between the 25th and 28th weeks of pregnancy, and the third measurement between the 35th and 38th weeks of pregnancy.
|
Umbilical artery waveform patterns can be obtained from either of the two arteries in the umbilical cord using color Doppler and pulsed Doppler.
The angle of the probe to the vessel should be below 60°.
It is important to perform the measurements from the freest point where the umbilical vessels are not compressed.
The umbilical artery waveform shows systolic (heart contraction) and diastolic (heart relaxation) flow.
Pulsatility index (PI) are calculated.
|
The first measurement will be performed between the 20th and 24th weeks of pregnancy, the second measurement between the 25th and 28th weeks of pregnancy, and the third measurement between the 35th and 38th weeks of pregnancy.
|
|
middle cerebral artery blood flow
Time Frame: The first measurement will be performed between the 20th and 24th weeks of pregnancy, the second measurement between the 25th and 28th weeks of pregnancy, and the third measurement between the 35th and 38th weeks of pregnancy.
|
To obtain an ideal waveform in the middle cerebral artery (MCA) measurement, the Circle of Willis and the proximal MCA color flow mapping just caudal to the transthalamic plane will be visualized.
The probe will then be placed at the proximal third of the MCA, close to its origin from the internal carotid artery, keeping the insonation angle as close to 0° as possible [48].
Doppler indices will be calculated by obtaining 3 consecutive waveforms.
Middle cerebral artery Doppler measurement is routinely performed in pregnancy examinations to assess pregnancy complications.
Measurements will be performed by an obstetrician during routine pregnancy check-ups.
|
The first measurement will be performed between the 20th and 24th weeks of pregnancy, the second measurement between the 25th and 28th weeks of pregnancy, and the third measurement between the 35th and 38th weeks of pregnancy.
|
|
vulvovaginal blood flow
Time Frame: The first measurement will be performed between the 20th and 24th weeks of pregnancy, the second measurement between the 25th and 28th weeks of pregnancy, and the third measurement between the 35th and 38th weeks of pregnancy.
|
Doppler ultrasonography (Voluson E8, GE Healthcare, Salzburg, Austria) will be used to identify the dorsal clitoral artery, sampled from the outer surface of the clitoral body, in a longitudinal plane.
With the same longitudinal approach, the terminal branch of the posterior labial artery (a branch of the internal pudendal artery) will be visualized posterolaterally to the labia majora (approximately 2 cm away from the clitoral hood).
For both the clitoral and labial arteries, the insonation angle will always be adjusted (<40°) to obtain maximum color intensity.
Once adequate signals are obtained, blood flow velocity waveforms will be recorded by placing the spectral Doppler gate along the vessel and activating the pulsed Doppler mode.
The Pulsatility Index (PI), defined as the difference between peak systolic and end-diastolic flow divided by the mean maximum flow velocity, will be calculated electronically by the machine.
|
The first measurement will be performed between the 20th and 24th weeks of pregnancy, the second measurement between the 25th and 28th weeks of pregnancy, and the third measurement between the 35th and 38th weeks of pregnancy.
|
|
pelvic floor muscle function
Time Frame: The first measurement will be performed between the 20th and 24th weeks of pregnancy, the second measurement between the 25th and 28th weeks of pregnancy, and the third measurement between the 35th and 38th weeks of pregnancy.
|
The patient is asked to squeeze one or two fingers placed inside the vagina, and the strength of the contraction felt around the fingers is graded according to various scales.
Physiotherapists most commonly use the Modified Oxford Grading Scale developed by Laycock in clinical practice to measure pelvic floor muscle strength.
In 2001, the PERFECT Scale was developed by Laycock.
The PERFECT Scale allows for the evaluation of the strength (P).
|
The first measurement will be performed between the 20th and 24th weeks of pregnancy, the second measurement between the 25th and 28th weeks of pregnancy, and the third measurement between the 35th and 38th weeks of pregnancy.
|
|
pelvic floor muscle function
Time Frame: The first measurement will be performed between the 20th and 24th weeks of pregnancy, the second measurement between the 25th and 28th weeks of pregnancy, and the third measurement between the 35th and 38th weeks of pregnancy.
|
The patient is asked to squeeze one or two fingers placed inside the vagina, and the strength of the contraction felt around the fingers is graded according to various scales.
Physiotherapists most commonly use the Modified Oxford Grading Scale developed by Laycock in clinical practice to measure pelvic floor muscle strength.
In 2001, the PERFECT Scale was developed by Laycock.
The PERFECT Scale allows for the evaluation of the endurance (E).
|
The first measurement will be performed between the 20th and 24th weeks of pregnancy, the second measurement between the 25th and 28th weeks of pregnancy, and the third measurement between the 35th and 38th weeks of pregnancy.
|
|
pelvic floor muscle function
Time Frame: The first measurement will be performed between the 20th and 24th weeks of pregnancy, the second measurement between the 25th and 28th weeks of pregnancy, and the third measurement between the 35th and 38th weeks of pregnancy.
|
The patient is asked to squeeze one or two fingers placed inside the vagina, and the strength of the contraction felt around the fingers is graded according to various scales.
Physiotherapists most commonly use the Modified Oxford Grading Scale developed by Laycock in clinical practice to measure pelvic floor muscle strength.
In 2001, the PERFECT Scale was developed by Laycock.
The PERFECT Scale allows for the evaluation fast-twitch muscle fiber performance (F).
|
The first measurement will be performed between the 20th and 24th weeks of pregnancy, the second measurement between the 25th and 28th weeks of pregnancy, and the third measurement between the 35th and 38th weeks of pregnancy.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Özge Çeliker Tosun, professor, Dokuz Eylul University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- CelalBayarU11
- Dokuz Eylul University (Other Identifier: Dokuz Eylul University medical school ethics committee)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pregnancy
-
Far Eastern Memorial HospitalCompletedCornual PregnancyTaiwan
-
Peking Union Medical College HospitalPeking Union Medical CollegeUnknownPregnancy | Pregnancy Related | Infant | Pregnancy Disease | Risk FactorChina
-
Meir Medical CenterRecruiting
-
Bagcilar Training and Research HospitalRecruitingEctopic PregnancyTurkey (Türkiye)
-
MELISA Institute Genomics & Proteomics Research...RecruitingHealthy | Pregnancy | Early Pregnancy | Early Pregnancy Loss | ChildbirthChile
-
Turku University HospitalUniversity of TurkuCompleted
-
Ufuk UniversityNot yet recruitingPregnancy Complications | Pregnancy Loss | Pregnancy Preterm
-
Hadassah Medical OrganizationCompleted
-
Centre Hospitalier Universitaire de Saint EtienneCompletedProlonged PregnancyFrance
-
Zagazig UniversityCompleted
Clinical Trials on Exercise
-
National Institute of Neurological Disorders and...TerminatedTraumatic Brain InjuryUnited States
-
University of Texas, El PasoRecruitingKnee Osteoarthritis | Knee Pain Chronic | Central Pain SyndromeUnited States
-
Aksaray University Training and Research HospitalCompletedExercise Training | Lactate Blood Increase | Cognitive Functions | BDNFTurkey (Türkiye)
-
University of Alabama at BirminghamCompletedCystic FibrosisUnited States
-
University of LisbonFundação para a Ciência e a TecnologiaActive, not recruiting
-
University of Missouri-ColumbiaCompleted
-
University of AlcalaCompletedMyofascial Pain | Myofascial Pain Syndrome | Post Needling Soreness | Myofascial Trigger Point PainSpain
-
Toronto Rehabilitation InstituteCompletedAcute Myeloid LeukemiaCanada
-
Bayero University Kano, NigeriaCompletedChronic Low Back PainNigeria
-
University College CorkRecruitingDepressive Disorder, MajorIreland